366 A randomized double-blind placebo-controlled phase III study evaluating perioperative toripalimab combined with platinum-based doublet chemotherapy in resectable stage III NSCLC

医学 多西紫杉醇 培美曲塞 内科学 化疗 肺癌 肿瘤科 安慰剂 围手术期 新辅助治疗 外科 顺铂 癌症 病理 乳腺癌 替代医学
作者
Wenxiang Wang,Lin Wu,Wei Zhang,Shun Lü,Haohui Fang,Guohua Yu,Ming Zhou,Wenqun Xing,Qixun Chen,Xingya Li,Nong Yang,Minhua Ye,Wentao Fang,Yunchao Huang,Jichun Liu,Lijie Tan,Xiaosheng Hang,Wengang Zhang,Liwei Zhang,Jun Chen
出处
期刊: 卷期号:: A223.2-A224 被引量:2
标识
DOI:10.1136/jitc-2020-sitc2020.0366
摘要

Background Surgery remains the mainstay of treatment for resectable stage III non-small cell lung cancer (NSCLC). The preliminary results from some pilot trials have shown that neoadjuvant immunotherapy in NSCLC is safe and tolerable.1 2Hypothesizing that neoadjuvant toripalimab (a humanized anti-PD-1 antibody) plus chemotherapy can improve the outcome in resectable NSCLC, we are conducting a randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of toripalimab plus platinum-based doublet chemotherapy as neoadjuvant/adjuvant therapy for patients with resectable stage III NSCLC. Methods This ongoing study enrolls patients aged 18–70 years with treatment-naïve, histopathologically confirmed resectable stage III NSCLC without EGFR mutation or ALK translocation, ECOG PS 0–1, and adequate organ function. Eligible subjects are randomized (1:1) into experimental or control group, to receive perioperative toripalimab 240 mg or placebo combined with chemotherapy for 4 cycle in total (Docetaxel 60–75 mg/m2 or Paclitaxel 175 mg/m2 with platinum [squamous histology] or Pemetrexed 500 mg/m2 with platinum [non-squamous histology]) every 3 weeks for three cycles followed by surgery, and one more cycle after surgery, then monotherapy of toripalimab 240 mg or placebo every 3 weeks up to 13 cycles is delivered. Adjuvant radiotherapy is allowed. Randomization is stratified by tumor stage(IIIA vs IIIB), pathological type (squamous vs non-squamous), PD-L1 expression (PD-L1≥1% vs <1% or not evaluable) and planned surgical procedure (pneumonectomy vs lobectomy). Radiographic response is assessed within 4–6 weeks after last dose of neoadjuvant therapy, at 30 days after surgery and every 12 weeks thereafter. Primary endpoints are major pathologic response (MPR) rate evaluated by blind independent central pathology review (BIPR-MPR) and event-free survival evaluated by investigator (INV-EFS). Secondary endpoints include pathologic complete response (pCR) rate evaluated by BIPR and investigators (BIPR-pCR and INV-pCR), disease-free survival (DFS), 2–3 years OS rate, OS, safety, and feasibility of surgery. Exploratory endpoints are potential correlations between biomarkers and efficacy. A stratified Cochran Mantel Haenszel method will be used to assess binary endpoints. A Kaplan-Meier method, a stratified log-rank test and a stratified Cox proportional hazards model will be used to assess survival endpoints.Planned enrollment is 406 patients. The study is actively enrolling at 52 Chinese sites. Results N/A Conclusions N/A Acknowledgements N/A Trial Registration The Clinical trials. gov no NCT04158440 Ethics Approval This study was approved by the Ethics Board of all the involved sites; Approval number of Shanghai Chest Hospital: LS1936 Consent N/A References Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer N Engl J Med 2018;378:1976–1986 Hellmann MD, Chaft JE, William WN Jr, et al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet oncol 2014;15:e42–50.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
科研通AI6.2的应助被XZM采纳,获得10
1秒前
1秒前
sing完成签到 ,获得积分10
2秒前
2秒前
Mortal完成签到 ,获得积分10
3秒前
3秒前
纯真正豪发布了新的文献求助10
5秒前
酷波er的应助被JXY189采纳,获得10
5秒前
5秒前
香蕉觅云的应助被长庚采纳,获得10
5秒前
研友_ngqgY8完成签到,获得积分10
6秒前
7秒前
初(*^▽^*)心的应助被李宏梅采纳,获得10
8秒前
章鱼发布了新的文献求助10
9秒前
10秒前
Steven发布了新的文献求助30
11秒前
12秒前
啊呜完成签到,获得积分10
12秒前
可靠的马丁完成签到,获得积分10
13秒前
Maestro_S的应助被沈恺恺采纳,获得10
14秒前
14秒前
14秒前
ingst完成签到 ,获得积分10
15秒前
大佬发布了新的文献求助10
16秒前
万能图书馆的应助被FZ采纳,获得10
17秒前
AAA袁氏茶馆完成签到,获得积分10
17秒前
无花果的应助被刘白采纳,获得10
17秒前
水煮电吹风的应助被LL采纳,获得10
17秒前
裴腾骏完成签到,获得积分10
17秒前
18秒前
科研通AI6.2的应助被zo采纳,获得10
19秒前
19秒前
浮云客发布了新的文献求助10
23秒前
23秒前
ChoHing发布了新的文献求助10
23秒前
25秒前
大佬完成签到,获得积分10
25秒前
25秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183667
求助须知:如何正确求助?哪些是违规求助? 9572953
关于积分的说明 21828185
捐赠科研通 7780853
什么是DOI,文献DOI怎么找? 3434031
关于科研通互助平台的介绍 2558251
邀请新用户注册赠送积分活动 2480500